Abstract: The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Type:
Grant
Filed:
April 14, 2022
Date of Patent:
July 16, 2024
Assignee:
ARO Biotherapeutics Company
Inventors:
Russell C. Addis, Zhanna Druzina, Robert V. Kolakowski, Steven G. Nadler, Karyn T. O'Neil, Yao Xin
Abstract: The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.
Type:
Grant
Filed:
October 14, 2020
Date of Patent:
October 10, 2023
Assignee:
Aro Biotherapeutics Company
Inventors:
Russell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin
Abstract: The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Type:
Grant
Filed:
October 14, 2020
Date of Patent:
April 18, 2023
Assignee:
ARO BIOTHERAPEUTICS COMPANY
Inventors:
Russell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin